Gilead Sciences Company Insiders
GILD Stock | USD 67.08 0.05 0.07% |
About 91 percent of Gilead Sciences' insiders are activelly selling. The analysis of the overall insider sentiment regarding Gilead Sciences suggests that quite a large number of insiders are panicking. Gilead Sciences employs about 18 K people. The company is managed by 42 executives with a total tenure of roughly 286 years, averaging almost 6.0 years of service per executive, having 428.57 employees per reported executive.
John Martin Chairman Chairman and CEO |
Daniel ODay Chairman Chairman of the Board, CEO |
Gilead Sciences' Insider Buying Vs Selling
9
Selling | Buying |
Latest Trades
2024-04-01 | Merdad Parsey | Disposed 2000 @ 72.96 | View | ||
2024-02-28 | Merdad Parsey | Disposed 2000 @ 73.18 | View | ||
2024-01-16 | Andrew D Dickinson | Disposed 5000 @ 85.78 | View | ||
2024-01-09 | Johanna Mercier | Disposed 8242 @ 85.23 | View | ||
2023-10-24 | Greg Stanton | Disposed @ 78.15 | |||
2023-10-17 | Andrew D Dickinson | Disposed 5000 @ 80 | View | ||
2023-09-26 | Greg Stanton | Acquired @ 75.53 | |||
2023-09-12 | Merdad Parsey | Disposed 1501 @ 76.99 | View | ||
2023-07-20 | Andrew D Dickinson | Disposed 5000 @ 80 | View | ||
2023-07-12 | Daniel S. Goldman | Disposed @ 76.38 | |||
2023-06-13 | Merdad Parsey | Disposed 1485 @ 76.9 | View |
Monitoring Gilead Sciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Gilead Sciences' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Gilead Sciences. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Gilead Sciences' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Gilead |
Gilead Sciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Gilead Sciences' future performance. Based on our forecasts, it is anticipated that Gilead will maintain a workforce of about 18000 employees by May 2024.Gilead Sciences' latest congressional trading
Congressional trading in companies like Gilead Sciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Gilead Sciences by those in governmental positions are based on the same information available to the general public.
2023-10-24 | Representative Greg Stanton | Acquired Under $15K | Verify | ||
2023-07-12 | Representative Daniel Goldman | Acquired $15K to $50K | Verify | ||
2022-01-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2021-12-21 | Senator Jerry Moran | Acquired Under $15K | Verify | ||
2021-11-10 | Representative Carol Devine Miller | Disposed $15K to $50K | Verify | ||
2021-01-21 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
2020-12-22 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
2020-12-18 | Representative Dean Phillips | Disposed Under $15K | Verify | ||
2020-09-01 | Representative Ed Perlmutter | Acquired Under $15K | Verify | ||
2020-07-08 | Representative Roger W. Marshall | Acquired Under $15K | Verify | ||
2020-06-29 | Representative William R. Timmons | Acquired Under $15K | Verify | ||
2020-02-20 | Representative Mikie Sherrill | Acquired Under $15K | Verify | ||
2019-10-25 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
2019-09-19 | Representative Bill Flores | Acquired Under $15K | Verify | ||
2019-03-11 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2018-04-23 | Senator Angus S. King, Jr. | Acquired Under $15K | Verify | ||
2018-02-22 | Senator James M. Inhofe | Acquired $50K to $100K | Verify | ||
2017-09-20 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
2017-03-02 | Senator Susan M. Collins | Acquired Under $15K | Verify | ||
2014-04-14 | Senator Susan M Collins | Acquired Under $15K | Verify |
Gilead Sciences Management Team Effectiveness
The company has return on total asset (ROA) of 0.0978 % which means that it generated a profit of $0.0978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2554 %, meaning that it created $0.2554 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.22. The current year's Return On Capital Employed is expected to grow to 0.19. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.9 B, whereas Total Current Assets are forecasted to decline to about 10.8 B.The current year's Common Stock Shares Outstanding is expected to grow to about 1.5 B, whereas Net Income Applicable To Common Shares is forecasted to decline to about 4.9 B.
Gilead Sciences Workforce Comparison
Gilead Sciences is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 551,600. Gilead Sciences holds roughly 18,000 in number of employees claiming about 3% of equities under Health Care industry.
Gilead Sciences Profit Margins
The company has Profit Margin (PM) of 0.21 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 1.07 | 0.7799 |
|
|
Gilead Sciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gilead Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gilead Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Gilead Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 1.3333 | 36 | 27 | 1,266,642 | 267,582 |
2023-12-01 | 0.5333 | 8 | 15 | 18,447 | 31,737 |
2023-09-01 | 0.5263 | 10 | 19 | 38,304 | 60,680 |
2023-06-01 | 1.6923 | 22 | 13 | 112,501 | 38,058 |
2023-03-01 | 1.25 | 40 | 32 | 1,128,676 | 266,434 |
2022-12-01 | 0.4762 | 10 | 21 | 36,382 | 88,490 |
2022-09-01 | 0.5 | 8 | 16 | 16,694 | 80,872 |
2022-06-01 | 1.625 | 39 | 24 | 299,224 | 63,903 |
2022-03-01 | 1.2571 | 44 | 35 | 1,633,427 | 229,097 |
2021-12-01 | 0.8333 | 5 | 6 | 9,450 | 12,612 |
2021-09-01 | 1.1429 | 8 | 7 | 23,658 | 41,537 |
2021-06-01 | 2.4 | 24 | 10 | 168,644 | 74,893 |
2021-03-01 | 1.2727 | 42 | 33 | 1,402,589 | 189,827 |
2020-12-01 | 1.1818 | 13 | 11 | 53,390 | 49,439 |
2020-09-01 | 0.8571 | 6 | 7 | 13,446 | 19,331 |
2020-06-01 | 1.28 | 32 | 25 | 131,108 | 91,601 |
2020-03-01 | 0.8571 | 48 | 56 | 947,653 | 442,930 |
2019-12-01 | 0.48 | 12 | 25 | 211,478 | 343,962 |
2019-09-01 | 1.0 | 7 | 7 | 191,617 | 26,356 |
2019-06-01 | 1.3913 | 32 | 23 | 178,370 | 97,544 |
2019-03-01 | 2.7692 | 36 | 13 | 929,034 | 83,253 |
2018-12-01 | 0.625 | 10 | 16 | 558,351 | 725,117 |
2018-09-01 | 0.75 | 9 | 12 | 155,008 | 304,469 |
2018-06-01 | 0.7083 | 34 | 48 | 457,671 | 1,147,635 |
2018-03-01 | 0.9298 | 53 | 57 | 1,234,973 | 909,350 |
2017-12-01 | 0.5172 | 15 | 29 | 492,516 | 994,620 |
2017-09-01 | 0.6471 | 22 | 34 | 425,338 | 1,019,734 |
2017-06-01 | 1.5882 | 27 | 17 | 339,440 | 487,336 |
2017-03-01 | 1.5385 | 40 | 26 | 1,350,400 | 687,274 |
2016-12-01 | 0.3214 | 9 | 28 | 435,518 | 1,405,006 |
2016-09-01 | 0.5806 | 18 | 31 | 1,298,480 | 2,019,883 |
2016-06-01 | 0.875 | 42 | 48 | 896,658 | 1,544,093 |
2016-03-01 | 1.2424 | 41 | 33 | 1,551,153 | 1,165,038 |
2015-12-01 | 0.3625 | 29 | 80 | 1,055,327 | 2,145,346 |
2015-09-01 | 0.4167 | 30 | 72 | 1,263,033 | 2,600,238 |
2015-06-01 | 0.6897 | 60 | 87 | 1,071,786 | 2,039,036 |
2015-03-01 | 0.6944 | 50 | 72 | 2,155,801 | 2,132,415 |
2014-12-01 | 0.3488 | 30 | 86 | 1,099,268 | 2,489,076 |
2014-09-01 | 0.4118 | 28 | 68 | 850,943 | 1,710,788 |
2014-06-01 | 0.7742 | 48 | 62 | 776,261 | 1,389,602 |
2014-03-01 | 0.6269 | 42 | 67 | 1,189,150 | 1,990,741 |
2013-12-01 | 0.32 | 8 | 25 | 523,826 | 1,389,573 |
2013-09-01 | 0.65 | 26 | 40 | 888,373 | 1,771,840 |
2013-06-01 | 1.4091 | 31 | 22 | 2,552,914 | 2,599,503 |
2013-03-01 | 0.6875 | 11 | 16 | 327,177 | 462,178 |
2012-12-01 | 0.575 | 23 | 40 | 744,171 | 1,268,288 |
2012-09-01 | 0.6667 | 22 | 33 | 491,253 | 568,788 |
2012-06-01 | 2.6667 | 32 | 12 | 142,089 | 44,794 |
2012-03-01 | 0.9091 | 20 | 22 | 514,883 | 374,311 |
2011-12-01 | 0.8333 | 5 | 6 | 201,000 | 15,566 |
2011-09-01 | 1.0 | 7 | 7 | 26,671 | 22,736 |
2011-06-01 | 2.3077 | 30 | 13 | 164,938 | 47,570 |
2011-03-01 | 1.1667 | 14 | 12 | 587,746 | 62,706 |
2010-12-01 | 0.4545 | 5 | 11 | 126,000 | 246,747 |
2010-09-01 | 3.5 | 7 | 2 | 173,873 | 154,000 |
2010-06-01 | 8.0 | 32 | 4 | 191,503 | 15,100 |
2010-03-01 | 1.0 | 18 | 18 | 419,444 | 307,236 |
2009-12-01 | 0.5625 | 9 | 16 | 185,000 | 355,520 |
2009-09-01 | 0.9091 | 20 | 22 | 501,469 | 907,765 |
2009-06-01 | 1.3158 | 25 | 19 | 442,080 | 626,500 |
2009-03-01 | 0.7917 | 19 | 24 | 630,200 | 697,742 |
2008-12-01 | 0.5556 | 15 | 27 | 536,850 | 831,037 |
2008-09-01 | 0.375 | 15 | 40 | 667,528 | 853,200 |
2008-06-01 | 0.156 | 22 | 141 | 702,213 | 759,587 |
2008-03-01 | 0.1391 | 21 | 151 | 881,400 | 732,627 |
2007-12-01 | 0.0412 | 7 | 170 | 343,000 | 718,550 |
2007-09-01 | 0.1765 | 9 | 51 | 420,000 | 476,000 |
2007-06-01 | 0.2 | 18 | 90 | 612,696 | 823,592 |
2007-03-01 | 0.1868 | 17 | 91 | 683,000 | 516,920 |
2006-12-01 | 0.0839 | 12 | 143 | 446,600 | 786,670 |
2006-09-01 | 0.0885 | 10 | 113 | 282,381 | 551,792 |
2006-06-01 | 0.4815 | 13 | 27 | 398,750 | 314,500 |
2006-03-01 | 0.2466 | 18 | 73 | 781,500 | 633,710 |
2005-12-01 | 0.1772 | 14 | 79 | 370,386 | 665,776 |
2005-09-01 | 0.5652 | 13 | 23 | 463,562 | 509,704 |
2005-06-01 | 0.1702 | 24 | 141 | 1,081,672 | 954,662 |
2005-03-01 | 0.6471 | 11 | 17 | 652,296 | 402,889 |
2004-12-01 | 0.4516 | 14 | 31 | 628,064 | 665,566 |
2004-09-01 | 0.4074 | 11 | 27 | 140,993 | 259,120 |
2004-06-01 | 1.5556 | 14 | 9 | 249,353 | 164,000 |
2004-03-01 | 0.8462 | 22 | 26 | 542,500 | 268,515 |
2003-12-01 | 0.3333 | 5 | 15 | 212,000 | 311,500 |
2003-09-01 | 0.3284 | 22 | 67 | 361,457 | 609,258 |
2003-06-01 | 1.0 | 2 | 2 | 716.00 | 33,880 |
Gilead Sciences Notable Stakeholders
A Gilead Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gilead Sciences often face trade-offs trying to please all of them. Gilead Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gilead Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John Martin | Chairman and CEO | Profile | |
Daniel ODay | Chairman of the Board, CEO | Profile | |
Kathleen Watson | Executive Vice President - Human Resources | Profile | |
John McHutchison | Executive Vice President - Clinical Research | Profile | |
Andrew Cheng | Executive Vice President - HIV Therapeutics and Development Operations | Profile | |
Andrew Dickinson | Executive Vice President - Corporate Development and Strategy | Profile | |
William Lee | Executive Vice President - Research | Profile | |
Martin Silverstein | Executive Vice President - Strategy | Profile | |
Paul Carter | Executive Vice President - Commercial Operations | Profile | |
Diana Brainard | Senior Vice President HIV and Emerging Viral Infections | Profile | |
James Meyers | Executive Vice President - Worldwide Commercial Operations | Profile | |
Katie Watson | Executive Vice President of Human Resources | Profile | |
Jyoti Mehra | Executive Vice President of Human Resources | Profile | |
Laura Hamill | Executive Vice President - Worldwide Commercial Operations | Profile | |
Taiyin Yang | Executive Vice President - Pharmaceutical Development and Manufacturing | Profile | |
Robin Washington | CFO and Executive VP | Profile | |
John Milligan | Pres and COO | Profile | |
Kevin Young | COO | Profile | |
Brett Pletcher | Executive VP and General Counsel | Profile | |
Gregg Alton | Executive VP of Corporate and Medical Affairs and Secretary | Profile | |
Norbert Bischofberger | Chief Scientific Officer and Executive VP of RandD | Profile | |
Gayle Wilson | Independent Director | Profile | |
Jacqueline Barton | Director | Profile | |
John Madigan | Independent Director | Profile | |
Kevin Lofton | Independent Director | Profile | |
Carla Hills | Independent Director | Profile | |
John Cogan | Lead Independent Director | Profile | |
Nicholas Moore | Independent Director | Profile | |
Kelly Kramer | Director | Profile | |
Per WoldOlsen | Independent Director | Profile | |
Harish Manwani | Director | Profile | |
Etienne Davignon | Independent Director | Profile | |
Richard Whitley | Independent Director | Profile | |
Sandra Patterson | Corporate VP | Profile | |
Michael Quigley | VP Biology | Profile | |
Linda Higgins | Innovation Research | Profile | |
Deborah Telman | General Affairs | Profile | |
Jacquie CFA | Vice Relations | Profile | |
Flavius MD | Executive Research | Profile | |
Johanna Mercier | Chief Commercial Officer | Profile | |
Diane Wilfong | Corp VP | Profile | |
Rudolf Ertl | Canada, Australia | Profile |
About Gilead Sciences Management Performance
The success or failure of an entity such as Gilead Sciences often depends on how effective the management is. Gilead Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gilead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gilead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.21 | 0.22 | |
Return On Capital Employed | 0.18 | 0.19 | |
Return On Assets | 0.09 | 0.1 | |
Return On Equity | 0.25 | 0.26 |
The data published in Gilead Sciences' official financial statements usually reflect Gilead Sciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Gilead Sciences. For example, before you start analyzing numbers published by Gilead accountants, it's critical to develop an understanding of what Gilead Sciences' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Gilead Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gilead Sciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Gilead Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gilead Sciences. Please utilize our Beneish M Score to check the likelihood of Gilead Sciences' management manipulating its earnings.
Gilead Sciences Workforce Analysis
Traditionally, organizations such as Gilead Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gilead Sciences within its industry.Gilead Sciences Manpower Efficiency
Return on Gilead Sciences Manpower
Revenue Per Employee | 1.5M | |
Revenue Per Executive | 645.6M | |
Net Income Per Employee | 311.8K | |
Net Income Per Executive | 133.6M | |
Working Capital Per Employee | 266.9K | |
Working Capital Per Executive | 114.4M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.